Mersana Therapeutics (NASDAQ:MRSN) 报告季度每股亏损$(0.11)，比分析师一致预期的$(0.15)高出26.67%。 这比去年同期的每股亏损$(0.16)增长了31.25%。公司报告季度销售额为$1636万美元，比分析师一致预期的$771万美元高出112.20%。 这比去年同期的销售额$1070万美元增长了52.89%。
以上内容来自Benzinga Earnings专栏，原文如下：
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 31.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $16.36 million which beat the analyst consensus estimate of $7.71 million by 112.20 percent. This is a 52.89 percent increase over sales of $10.70 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.